Risk stratification in multiple myeloma: Are we there yet?
Meera MohanCarolina SchinkePublished in: British journal of haematology (2024)
The second revision of international staging system (R2-ISS) shows promise in patients with multiple myeloma treated with a regimen of novel agent-based induction therapy, autologous stem cell transplant and maintenance therapy, but challenges persist. This study by Alzahrani et al. underscores the importance of refining risk assessment tools for tailored treatment strategies. Commentary on: Alzahrani et al. Impact of revised international staging system 2 (R2-ISS) risk stratification on outcomes of patients with multiple myeloma receiving autologous hematopoietic stem cell transplantation. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19384.
Keyphrases
- multiple myeloma
- stem cells
- risk assessment
- cell therapy
- lymph node
- bone marrow
- total knee arthroplasty
- pet ct
- platelet rich plasma
- social media
- acute myeloid leukemia
- heavy metals
- adipose tissue
- human health
- health information
- mesenchymal stem cells
- machine learning
- big data
- skeletal muscle
- newly diagnosed
- weight loss